Imagion Biosystems is expanding its collaboration agreement with Siemens Healthineers for an additional two years.
In addition to extending the existing agreement with Siemens Healthcare of Australia, the companies have agreed to collaborate in the U.S. through Siemens Medical Solutions USA. The U.S. extension will continue development of Imagion's planned multisite phase II study for its MagSense HER2 MRI contrast agent.
Through the collaboration, Siemens Healthineers will offer its expertise to Imagion's clinical advisors and investigators. Imagion said the goal for its contrast agent is to improve cancer diagnosis and patient care while using nonradioactive imaging methods.
